India Ophthalmic Clinical Trials Market by Product (Devices, Surgical Devices, Intraocular Lenses, Aspheric IOLs, Toric IOLs, Multifocal IOLs, Monofocal IOLs, Others), By Indication (Macular Degeneration, Glaucoma, Dry Eye Disease, Retinopathy, Uveitis, Macular Edema, Blepharitis, Cataract, Optic Neuropathy, Others ), by Phase (Preclinical, Discovery, Clinical, Phase I, Phase II, Phase III, Phase
Published Date: December - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Chemicals | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationIndia Ophthalmic Clinical Trials Market by Product (Devices, Surgical Devices, Intraocular Lenses, Aspheric IOLs, Toric IOLs, Multifocal IOLs, Monofocal IOLs, Others), By Indication (Macular Degeneration, Glaucoma, Dry Eye Disease, Retinopathy, Uveitis, Macular Edema, Blepharitis, Cataract, Optic Neuropathy, Others ), by Phase (Preclinical, Discovery, Clinical, Phase I, Phase II, Phase III, Phase
| Forecast Period | 2025-2029 |
| Market Size (2023) | USD 37.63 million |
| CAGR (2024-2029) | 5.42% |
| Fastest Growing Segment | Retinopathy Segment |
| Largest Market | West India |
Market Overview
India Ophthalmic Clinical Trials Market has valued at USD 37.63 billion in 2023 and is anticipated to project an impressive growth in the forecast period with a CAGR of 5.42% through 2029. Ophthalmic clinical trials are research studies conducted to evaluate the safety, efficacy, and effectiveness of medical interventions, treatments, drugs, devices, or surgical procedures related to eye health and vision. These trials are designed to gather scientific evidence and data that inform medical decisions, regulatory approvals, and advancements in the field of ophthalmology. Ophthalmic clinical trials aim to improve the understanding and management of various eye diseases and conditions, as well as to develop new treatments and technologies. Ophthalmic clinical trials involve participation from individuals who have the specific eye condition or disease under investigation. Participants may include those with conditions such as glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, cataracts, myopia, and more. Clinical trials use defined endpoints or outcomes to measure the effects of interventions. These can include improvements in visual acuity, reduction in eye pressure, changes in retinal thickness, or quality of life measures. Ophthalmology has seen significant technological advancements, including innovative diagnostic tools, surgical techniques, and drug delivery systems. These advancements drive the need for clinical trials to assess the safety and efficacy of new technologies and treatments. The India Ophthalmic Clinical Trials Market represents an untapped potential due to its large and diverse patient population. This presents opportunities for pharmaceutical companies, biotech firms, and research institutions to conduct trials and develop treatments catering to the Indian population's specific needs.
Key Market Drivers
Advancements in Medical Technology
Advancements in medical technology have significantly impacted the landscape of clinical trials across various medical fields, including ophthalmology. These advancements have streamlined processes, improved data collection, enhanced patient experiences, and contributed to the overall efficiency and effectiveness of clinical trials. Telemedicine platforms and remote monitoring solutions enable researchers to remotely track patients' health and collect data, reducing the need for frequent in-person visits. This is particularly relevant in ophthalmology, where remote imaging and visual assessments can be conducted, contributing to patient convenience and trial efficiency. EHR systems facilitate the efficient collection and management of patient data. Integrating EHRs with clinical trial databases streamlines data capture, reduces errors, and enhances data quality. Advanced digital imaging technologies, such as optical coherence tomography (OCT) and fundus photography, enable precise and non-invasive assessments of ocular structures. These technologies are crucial for tracking disease progression and treatment efficacy in ophthalmic clinical trials. The integration of big data analytics and artificial intelligence (AI) allows for the efficient analysis of large datasets, identifying patterns, correlations, and potential biomarkers. AI-driven algorithms can assist in patient recruitment, predict outcomes, and optimize trial designs. Mobile apps and wearable devices enable patients to report their symptoms and experiences in real time. This direct patient input provides valuable insights into treatment effects and enhances patient engagement. Blockchain technology offers enhanced data security and transparency in clinical trials. It can be used to securely store, share, and track trial-related data while ensuring data integrity. Technology enables the implementation of adaptive trial designs, where trial parameters can be adjusted based on interim results. This flexibility improves trial efficiency and the likelihood of successful outcomes. Electronic informed consent (eConsent) platforms provide detailed trial information to participants and allow them to provide consent electronically. These platforms enhance patient understanding and involvement in the trial process. Virtual reality and simulation technologies are used to replicate surgical procedures or treatment interventions. These tools assist in training investigators, enhancing procedural consistency, and reducing variability in trial outcomes. Biosensors and wearable devices can continuously monitor patient parameters, such as intraocular pressure or blood glucose levels, in real time. This data assists in understanding treatment effects and patient responses. Advancements in genomics and molecular diagnostics allow for personalized treatment approaches based on patients' genetic profiles. This precision medicine approach is increasingly relevant in clinical trials targeting specific patient subgroups. This factor will pace up the demand of India Ophthalmic Clinical Trials Market.
Rise in Rare and Orphan Diseases
Rare diseases, also known as orphan diseases, refer to medical conditions that affect a small number of individuals within a population. The exact definition of "rare" varies by region, but generally, a disease is considered rare when it affects a limited number of people. Rare diseases collectively affect a significant portion of the population. While each individual disease may be rare, there are thousands of different rare diseases, and together they impact millions of people across the country. Rare diseases are often characterized by their diversity. They can manifest in various ways, making diagnosis and treatment challenging. Due to their rarity, many rare diseases lack approved treatments. Patients with these conditions often face limited or no therapeutic options, leading to unmet medical needs. Conducting research on rare diseases can be challenging due to the limited number of affected individuals. This makes it difficult to recruit participants for clinical trials and gather sufficient data for analysis. Rare disease patient advocacy groups play a crucial role in raising awareness, advocating for research, and providing support to patients and their families. Many countries offer incentives, such as extended market exclusivity, tax benefits, and reduced regulatory fees, to encourage pharmaceutical companies to develop treatments for rare diseases. These incentives are often provided through orphan drug designation. The lack of treatments for rare diseases results in a high unmet medical need. Developing therapies for these conditions can significantly improve patients' quality of life and life expectancy. A substantial portion of rare diseases have a genetic basis, caused by mutations in specific genes. Advances in genomics have contributed to identifying the genetic underpinnings of many rare diseases. Patients with rare diseases often require specialized medical care from experts who are familiar with the unique challenges associated with these conditions. Rare diseases can have a significant emotional, financial, and social impact on patients and their families. Support networks and resources are essential for coping with challenges. This factor will help in the development of India Ophthalmic Clinical Trials Market.
Increasing Eye Disorders
Eye disorders, also known as eye diseases or ocular conditions, encompass a wide range of medical conditions that affect the eyes and visual system. These disorders can impact various parts of the eye, including the cornea, lens, retina, optic nerve, and surrounding structures. Eye disorders can cause changes in vision, discomfort, pain, and in some cases, can lead to permanent vision loss if not properly managed. Refractive Errors are conditions that affect the eye's ability to focus light correctly, leading to blurred vision. Cataracts involve the clouding of the eye's natural lens, leading to blurred vision, sensitivity to light, and reduced color perception. Cataracts are often age-related but can also be caused by other factors. Glaucoma is a group of eye disorders characterized by damage to the optic nerve, often due to increased intraocular pressure. It can lead to gradual vision loss and, if untreated, blindness. India is home to a population affected by glaucoma, which is the third leading cause of blindness in the country. Approximately 12 million individuals, representing 12.8 percent of the total blindness population, suffer from glaucoma. The prevalence of glaucoma in India ranges between 2.6 percent and 4.1 percent, with the latter being the most common cause of permanent blindness. Approximately 50 percent of individuals with glaucoma are unaware of their condition. Age-Related Macular Degeneration (AMD) affects the central part of the retina (macula), leading to central vision loss and difficulties with tasks that require fine detail, like reading or recognizing faces. Diabetic Retinopathy occurs in individuals with diabetes and can lead to damage of the blood vessels in the retina, causing vision loss if not managed properly. Dry eye occurs when the eyes do not produce enough tears, or the tears evaporate too quickly. This can result in discomfort, irritation, and blurry vision. This is a serious condition where the retina pulls away from its normal position, causing vision loss that can be sudden and severe. Conjunctivitis is the inflammation of the conjunctiva, the thin tissue covering the front of the eye. It can cause redness, itching, discharge, and discomfort. Strabismus refers to misalignment of the eyes, where one eye may look straight ahead while the other turns inward, outward, upward, or downward. This factor will accelerate the demand of India Ophthalmic Clinical Trials Market.
Key Market Challenges
Post-Trial Regulations and Market Access
Post-trial regulations and market access can indeed be challenging aspects for the India Ophthalmic Clinical Trials Market, as well as for clinical trials markets globally. After a successful clinical trial, the process of obtaining regulatory approvals for market access can be complex and time-consuming. This challenge is not unique to ophthalmic trials but extends to trials in various therapeutic areas. Following the completion of a clinical trial, researchers and sponsors must submit comprehensive data to regulatory authorities for review. This process involves scrutinizing trial results, safety data, efficacy outcomes, and overall risk-benefit profiles of the investigational product. Regulatory bodies, such as the Central Drugs Standard Control Organization (CDSCO) in India, conduct thorough evaluations before granting approval for the product to be marketed. Patient safety is of paramount importance in clinical trials. Regulatory agencies rigorously assess the safety profile of the investigational product to ensure that it meets acceptable safety standards. Any safety concerns or adverse events observed during the trial must be addressed and explained in detail during the regulatory review. The product's labeling and packaging must comply with regulatory requirements, including accurate representation of its indications, dosages, potential risks, and instructions for use. Even after obtaining regulatory approvals, companies may face challenges in bringing their products to market. Formulating effective market access strategies involves considerations such as pricing, reimbursement, distribution channels, and understanding the competitive landscape.
Patient Recruitment and Retention
Patient recruitment and retention are common challenges in clinical trials worldwide, and this challenge extends to the India Ophthalmic Clinical Trials Market as well. Ensuring enough eligible patients are recruited for a trial and retaining them throughout the trial's duration are crucial for obtaining accurate and meaningful results. Patients might not be aware of ongoing clinical trials or the potential benefits of participating in them due to a lack of awareness campaigns or information dissemination. There could be stigma associated with participating in clinical trials or misconceptions about the risks and benefits, leading to reluctance among potential participants. Patients in remote or underserved areas might have limited access to information about clinical trials, making it challenging to recruit participants from diverse populations. The involvement and support of treating physicians are crucial for patient recruitment. If healthcare professionals are not adequately informed about ongoing trials, they might not refer eligible patients. India is linguistically and culturally diverse. Information about trials might not be found at in all languages, and cultural considerations might impact patient willingness to participate. Explaining the trial's purpose, procedures, and potential risks in a way that patients can understand is essential for obtaining informed consent. This can be challenging if the trial involves complex procedures or medical jargon. Patients may have work, family, or logistical constraints that prevent them from participating, especially if the trial involves frequent visits to trial sites. Participants might move, change contact details, or lose interest, making it difficult to track their progress and maintain communication. Lengthy trial durations, frequent visits, and multiple assessments can lead to participant fatigue and dropouts.
Key Market Trends
Real-World Evidence
RWE (Real-World Evidence) refers to data collected from real-world patient experiences in routine clinical practice, rather than from controlled clinical trial environments. This data can provide insights into the effectiveness, safety, and outcomes of medical interventions in real-world settings. RWE complements data from traditional clinical trials by providing information about how treatments perform outside of controlled environments. In ophthalmology, it can offer insights into how interventions work in diverse patient populations with varying coexisting conditions.
Segmental Insights
Phase
In 2022, the India Ophthalmic Clinical Trials Market was dominated by the
Indication
In 2022, the India Ophthalmic Clinical Trials Market was dominated by the retinopathy segment with a share of around 24.81% and will probably expand in the forecasted years.
Service Type Insights
In 2022, the India Ophthalmic Clinical Trials market was dominated by clinical trial data management services with a share of around 33.39% and is predicted to continue expanding over the coming years.
Sponsor Type Insights
In 2022, the India Ophthalmic Clinical Trials market was dominated by pharmaceutical/biopharmaceutical companies with a share of around 41.85% and is predicted to continue expanding over the coming years.
Regional Insights
The West India region has established itself as the leader in the India Ophthalmic Clinical Trials market.
Recent Developments
- In 2022, Thecompany Entod Pharmaceuticals declared that it has been granted authorisationby the Directorate General of Genomics (DG) of India to conduct Phase 3clinical trials in the country for its 0.05 percent atropine-based eye dropsfor the treatment of eye disorders. This pharmaceutical company based in Maharashtra holdsmost of the market share in low-dose atropine eye drops. MYATRO (0.01 per cent)eye drops are primarily used to treat ocular disorders such as myopia, which isa condition in which a child can perceive nearby objects clearly but hasdifficulty in perceiving distant objects.
- In 2021, BioneedsIndia was acquired by Veeda Clinical Research to expand its research anddevelopment services. The acquisition was expected to boost the company'sservice offerings in the market.
- In 2019, PMI, asubsidiary of Promedica International, established a strategic alliance withDr. Ajit Agarwal's Eye Hospitals in India to carry out clinical trials. Thecollaboration was announced at the OCTANe Ophthalmology Technologies Summit(OTS), which was held at the Orange County Ophthalmology Centre in the UnitedStates. The collaboration will enable the two companies to expand theirclinical research services in the ophthalmology field by jointly enrolling andmanaging clinical studies in a broad patient population, while also ensuringthat the studies adhere to global and United States Food and DrugAdministration (FDA) qualification standards and requirements.
Key Market Players
- ProRelixServices LLP
- AbiogenesisClinpharm Pvt Ltd.
- VeedaClinical Research
- CatawbaResearch, LLC
- Novotech
- CatalystClinical Services Pvt. Ltd.
- NavitasLife Sciences
- VedicLifesciences Pvt Ltd.
- VimtaLabs Ltd
| By Product | By Indication | By Phase | By Service Type | By Sponsor Type | By Region |
|
|
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy